Recommendation of the retinological society, the German ophthalmological society and the professional association of ophthalmologists in Germany: Treatment of diabetic maculopathy;Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zur Therapie der diabetischen Makulopathie

Klinische Monatsblatter fur Augenheilkunde

Volumn 228, Issue 5, 2011, Pages 446-459

[No Author Info available]

Author keywords

anti VEGF; diabetic maculopathy; focal laser; retina

Indexed keywords

ARTICLE; DIABETIC RETINOPATHY; GERMANY; HUMAN; RETINA MACULOPATHY;

DIABETIC RETINOPATHY; GERMANY; HUMANS; OPHTHALMOLOGY; PRACTICE GUIDELINES AS TOPIC;

EID: 79955153320     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1273357     Document Type: Article

References (108)

1. Hammes H P., Lemmen K D., Jochmann C et al. Diabetic retinopathy and maculopathy. Dtsch Med Wochenschr 2006 131 1173-1175 (Pubitemid 44178348)
2. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 1047-1053 (Pubitemid 38579764)
3. Lipscombe L L., Hux J E. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995 - 2005: a population-based study. Lancet 2007 369 750-756 (Pubitemid 46321630)
4. Knauer C, Pfeiffer N. Blindness in Germany - today and in 2030. Ophthalmologe 2006 103 735-741 (Pubitemid 44407472)
5. Heintz E, Wirehn A B., Peebo B B. et al. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia 2010 53 2147-2154
6. Gelisken F, Ziemssen F. Diabetic maculopathy. Diagnosis and treatment. Ophthalmologe 2010 107 773-786
7. Klein R, Klein B E., Moss S E. The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab Rev 1989 5 559-570 (Pubitemid 19272666)
8. Klein R, Klein B E., Moss S E. et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984 91 1464-1474 (Pubitemid 15197017)
9. Brown M M., Brown G C., Sharma S et al. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002 120 481-484 (Pubitemid 34727820)
10. Hariprasad S M., Mieler W F., Grassi M et al. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol 2008 92 89-92
11. Clarke P M., Simon J, Cull C A. et al. Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36. Diabetes Care 2006 29 1506-1511 (Pubitemid 44127572)
12. Warrian K J., Lorenzana L L., Lankaranian D et al. The assessment of disability related to vision performance-based measure in diabetic retinopathy. Am J Ophthalmol 2010 149 852-860
13. Sharma S, Oliver-Fernandez A, Liu W et al. The impact of diabetic retinopathy on health-related quality of life. Curr Opin Ophthalmol 2005 16 155-159 (Pubitemid 40694973)
14. Miyamoto J M., Eraker S A. Parameter estimates for a QALY utility model. Med Decis Making 1985 5 191-213 (Pubitemid 16130642)
15. Chen E, Looman M, Laouri M et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010 26 1587-1597
16. Smith A F. The economic impact of ophthalmic services for persons with diabetes in the Canadian Province of Nova Scotia: 1993 - 1996. Ophthalmic Epidemiol 2001 8 13-25 (Pubitemid 32382338)
17. Ferber L von, Koster I, Hauner H. Medical costs of diabetic complications total costs and excess costs by age and type of treatment results of the German CoDiM Study. Exp Clin Endocrinol Diabetes 2007 115 97-104 (Pubitemid 46408116)
18. Matz H, Falk M, Gottinger W et al. Cost-benefit analysis of diabetic eye disease. Ophthalmologica 1996 210 348-353 (Pubitemid 26294896)
19. Lamoureux E L., Tai E S., Thumboo J et al. Impact of diabetic retinopathy on vision-specific function. Ophthalmology 2010 117 757-765
20. Bundesärztekammer, Kassenärztliche Bundesvereinigung, und Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fachgesellschaften. Nationale Versorgungsleitlinie Diabetes: Prävention und Therapie von Netzhautkomplikationen. 2010 http://www.versorgungsleitlinien.de/themen/ diabetes2/dm2-netzhaut/pdf/nvl-dm2netzhaut-lang.pdf
21. Hammes H P., Lemmen K D., Bertram B. Diabetische Retinopathie und Makulopathie (Praxis Leitlinien der Deutschen Diabetes-Gesellschaft). Diabetologie 2010 5 117-121
22. Browning D J., Altaweel M M., Bressler N M. et al. Diabetic macular edema: what is focal and what is diffuse? Am J Ophthalmol 2008 146 649-655, 655
23. Lee C M., Olk R J. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991 98 1594-1602
24. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991 98 786-806
25. Gangnon R E., Davis M D., Hubbard L D. et al. A severity scale for diabetic macular edema developed from ETDRS data. Invest Ophthalmol Vis Sci 2008 49 5041-5047
26. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology 1991 98 807-822
27. Elman M J., Aiello L P., Beck R W. et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010 117 1064-1077
28. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985 103 1796-1806
29. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991 98 766-785
30. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch Ophthalmol 1995 113 1144-1155
31. Fong D S., Segal P P., Myers F et al. Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1997 115 873-877
32. DRCR.net. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008 115 1447-1449, 1449
33. Beck R W., Edwards A R., Aiello L P. et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009 127 245-251
34. DRCR.net. The course of response to focal/grid photocoagulation for diabetic macular edema. Retina 2009 29 1436-1443
35. Roider J. Laser treatment of retinal diseases by subthreshold laser effects. Semin Ophthalmol 1999 14 19-26 (Pubitemid 29215307)
36. Schatz H, Madeira D, McDonald H R. et al. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991 109 1549-1551
37. Tranos P G., Topouzis F, Stangos N T. et al. Effect of laser photocoagulation treatment for diabetic macular oedema on patient's vision-related quality of life. Curr Eye Res 2004 29 41-49 (Pubitemid 39389440)
38. Ziemssen F, Wiedemann P, Kampik A et al. Intravitreal injections of medications in Germany. Contract situation and legal conditions. Ophthalmologe 2009 106 465-470
39. Retinologische Gesellschaft, Deutsche Ophthalmologische Gesellschaft und Berufsverband der Augenärzte. New aspects in the therapy of neovascular age related macular degeneration. Current position of the Retinological Society, the Germany Ophthalmologic Society and the Professional Union of Eye Doctors of Germany. Ophthalmologe 2009 106 457-464
40. Nicholson B P., Schachat A P. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010 248 915-930
41. Parravano M, Menchini F, Virgili G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2009 CD007419
42. Salam A, DaCosta J, Sivaprasad S. Anti-vascular endothelial growth factor agents for diabetic maculopathy. Br J Ophthalmol 2010 94 821-826
43. Klettner A, Mohle F, Roider J. Intracellular bevacizumab reduces phagocytotic uptake in RPE cells. Graefes Arch Clin Exp Ophthalmol 2010 248 819-824
44. Ziemssen F, Bartz-Schmidt K U., Grisanti S. (Side) effects of VEGF inhibition. Ophthalmologe 2006 103 484-492 (Pubitemid 43892187)
45. Chew E Y., Ferris III F L., Csaky K G. et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 2003 110 1683-1689 (Pubitemid 37025423)
46. Kook D, Wolf A, Kreutzer T et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008 28 1053-1060
47. Karim R, Tang B. Use of antivascular endothelial growth factor for diabetic macular edema. Clin Ophthalmol 2010 4 493-517
48. Goyal S, Lavalley M, Subramanian M L. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2010 249 15-27
49. Michaelides M, Kaines A, Hamilton R D. et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010 117 1078-1086
50. Arevalo J F., Sanchez J G., Fromow-Guerra J et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2009 247 735-743
51. Lam D S., Lai T Y., Lee V Y. et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 2009 29 292-299
52. Meyer C H., Ziemssen F, Heimann H et al. Intravitreal injection. Monitoring to avoid postoperative complications. Ophthalmologe 2008 105 143-155, 157
53. Shimura M, Nakazawa T, Yasuda K et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008 145 854-861
54. Biester S, Ziemssen F, Ulrich Bartz-Schmidt K et al. Is intravitreal bevacizumab treatment effective in diffuse diabetic macular edema? Graefes Arch Clin Exp Ophthalmol 2009 247 1575-1577
55. Soheilian M, Ramezani A, Obudi A et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009 116 1142-1150
56. Ahmadieh H, Ramezani A, Shoeibi N et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008 246 483-489 (Pubitemid 351447960)
57. Faghihi H, Roohipoor R, Mohammadi S F. et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008 18 941-948
58. Cunningham Jr E T., Adamis A P., Altaweel M et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005 112 1747-1757
59. Nguyen Q D., Shah S M., Khwaja A A. et al. Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 2010 117 2146-2151
60. Massin P, Bandello F, Garweg J G. et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010 33 2399-2405
61. Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE Study Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema. Ophtalmology 2011 118 615-625
62. Felinski E A., Antonetti D A. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 2005 30 949-957 (Pubitemid 43154689)
63. Gillies M C., McAllister I L., Zhu M et al. Pretreatment with intravitreal triamcinolone before laser for diabetic macular edema: 6-month results of a randomized, placebo-controlled trial. Invest Ophthalmol Vis Sci 2010 51 2322-2328
64. Steijns D, Duijvesz D, Breedijk M A. et al. Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: a systematic review. Acta Ophthalmol 2010 88 389-393
65. Mirshahi A, Shenazandi H, Lashay A et al. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema. Retina 2010 30 254-259
66. Spitzer M S., Ziemssen F, Yoruk E et al. Preservative-Free Triamcinolone versus Purified Triamcinolone Preparations. Klein Monatsbl Augenheilkd 2010 E-Pub
67. Chew E, Strauber S, Beck R et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology 2007 114 1190-1196
68. Martidis A, Duker J S., Greenberg P B. et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002 109 920-927 (Pubitemid 34465226)
69. Sutter F K., Simpson J M., Gillies M C. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004 111 2044-2049 (Pubitemid 39446723)
70. Lam D S., Chan C K., Mohamed S et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology 2007 114 2162-2167
71. Batioglu F, Ozmert E, Parmak N et al. Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. Int Ophthalmol 2007 27 299-306 (Pubitemid 47377474)
72. Gillies M C., Sutter F K., Simpson J M. et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006 113 1533-1538 (Pubitemid 44292310)
73. Park H Y., Yi K, Kim H K. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol 2005 19 122-127
74. Audren F, Lecleire-Collet A, Erginay A et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs. 2 mg. Am J Ophthalmol 2006 142 794-799
75. Taban M, Singh R P., Chung J Y. et al. Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis. Am J Ophthalmol 2007 144 50-54
76. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 2007 18 235-239 (Pubitemid 46624923)
77. Pearson P, Levy B, Cornstock T. Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multicenter clinical trial. Invest Ophthalmol Vis Sci 2006 47: E-Abstract 5442
78. Liu Y, Ke Q, Chen J et al. Sustained mechanical release of dexamethasone sodium phosphate from a foldable capsular vitreous body. Invest Ophthalmol Vis Sci 2010 51 1636-1642
79. Schwartz S G., Flynn Jr H W. Fluocinolone Acetonide Implantable Device for Diabetic Retinopathy. Curr Pharm Biotechnol 2011 12 347-351
80. Croxtall J D., Hal P T., Choudhury Q van et al. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A 549 cells. Br J Pharmacol 2002 135 511-519 (Pubitemid 34151184)
81. Yeung C K., Chan K P., Chan C K. et al. Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol 2004 48 236-242 (Pubitemid 38691431)
82. Kuppermann B D., Blumenkranz M S., Haller J A. et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007 125 309-317 (Pubitemid 46425557)
83. Haller J A., Kuppermann B D., Blumenkranz M S. et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010 128 289-296
84. Blumenkranz M S., Haller J A., Kuppermann B D. et al. Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina 2010 30 1090-1094
85. Boyer D S., Faber D, Gupta V. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2010 in press.
86. Lin J EC, Burke J A., Peng Q. Pharmacokinetics of a sustained release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2010 In Press
87. Haller J A., Qin H, Apte R S. et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010 117 1087-1093
88. Kumagai K, Furukawa M, Ogino N et al. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 2009 29 464-472
89. Patel J I., Hykin P G., Schadt M et al. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina 2006 26 5-13 (Pubitemid 44391745)
90. Flaxel C J., Edwards A R., Aiello L P. et al. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network. Retina 2010 30 1488-1495
91. Yamamoto T, Takeuchi S, Sato Y et al. Long-term follow-up results of pars plana vitrectomy for diabetic macular edema. Jpn J Ophthalmol 2007 51 285-291 (Pubitemid 47174606)
92. Navarro A, Pournaras J A., Hoffart L et al. Vitrectomy may prevent the occurrence of diabetic macular oedema. Acta Ophthalmol 2010 88 483-485
93. Park J H., Woo S J., Ha Y J. et al. Effect of vitrectomy on macular microcirculation in patients with diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2009 247 1009-1017
94. Laidlaw D A. Vitrectomy for diabetic macular oedema. Eye 2008 22 1337-1341
95. Dolgin E. In vision trial, some researchers would rather see double. Nat Med 2010 16 611
96. Lee C M., Olk R J. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991 98 1594-1602
97. Funatsu H, Noma H, Mimura T et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009 116 73-79
98. Baskin D E. Optical coherence tomography in diabetic macular edema. Curr Opin Ophthalmol 2010 21 172-177
99. Virgili G, Menchini F, Dimastrogiovanni A F. et al. Optical coherence tomography versus stereoscopic fundus photography or biomicroscopy for diagnosing diabetic macular edema: a systematic review. Invest Ophthalmol Vis Sci 2007 48 4963-4973 (Pubitemid 351260905)
100. Browning D J., McOwen M D., Bowen Jr R M. et al. Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. Ophthalmology 2004 111 712-715 (Pubitemid 38429668)
101. Michaelides M, Fraser-Bell S, Hamilton R et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina 2010 30 781-786
102. Chung E J., Roh M I., Kwon O W. et al. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 2008 28 957-963
103. Empfehlung der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands für die Durchführung von intravitrealen Injektionen (IVI). 2007 http://www.dog.org/publikationen
104. Scott I U., Edwards A R., Beck R W. et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007 114 1860-1867
105. Dehghan M H., Ahmadieh H, Ramezani A et al. A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 2008 28 7-17 (Pubitemid 351308679)
106. Bressler N M., Edwards A R., Beck R W. et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 2009 127 1566-1571
107. Gillies M C., Simpson J M., Gaston C et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009 116 2182-2187
108. Jaffe G J., Martin D, Callanan D et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006 113 1020-1027 (Pubitemid 43795240)